Three-dimensional conformal hypofractionated radiotherapy for brain metastases of non-small-cell lung carcinoma:implications for whole brain irradiation

Abstract

Abstract: Objective To evaluate the therapeutic effect of of whole brain irradiation (WBI) in the treatment of brain metastases of non-small-cell lung carcinoma and analyze the factors affecting the patients’ survival. Methods Ninety-three cases of brain metastases of non-small-cell lung carcinoma receiving radiotherapy between January 1998 and February 2004 were retrospectively reviewed. Of these patients, 68 were treated with three-dimensional conformal hypofractionated radiotherapy (3D-CRT) following WBI, while the other 25 underwent 3D-CRT alone. Kaplan-Meier method was used to analyze the survival rate and local control rate, and Cox proportional hazards model employed for determining prognostic factors influencing the patients’ survival. Results The overall median actuarial survival of the patients was 14 months in the 3D-CRT+WBI group with 1- and 2-year actuarial survival rates of 50% and 27%, respectively, showing no significant difference from 3D-CRT group, which had a median survival of 11 months and 1- and 2-year survival rates of 45% and 15% (P=0.502, log-rank test). Actuarial 1-year local control rate in 3D-CRT+WBI group was 90% as compared to 70% in 3D-CRT group (P=0.028, log-rank test). In multivariate analyses, active extracranial disease (P=0.002) and Karnofsky Performance Scale score (P=0.034)were identified as the independent prognostic factors for the patients’ survival. Conclusion WBI prior to 3D-CRT does not benefit the patients with brain metastases of non-small cell lung carcinoma for their survival, but may help improve the local control rate.

CLC Number:

R734.2

QIU Xing-sheng, CHEN Long-hua, CHEN Yong-qing. Three-dimensional conformal hypofractionated radiotherapy for brain metastases of non-small-cell lung carcinoma:implications for whole brain irradiation[J]. Journal of Southern Medical University, 2005, 25(11): 1375-1378.

References

[1] Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups and prognosis[J]. J Clin Oncol, 1988, 6(9): 1474-80.
[2] Boyd TS, Mehta MP. Stereotactic radiosurgery for brain metastases (Review)[J].Oncology, 1999, 13: 1397-409.
[3] Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial ofmotexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points[J]. J Clin Oncol, 2002, 20: 3445-53.
[4] Westphal M, Heese O. Intracranial metastases: therapeutic options[J]. Ann Onc, 2003, 14(3): iii4-10.
[5] Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases[J].Int J Radiat Oncol Biol Phys,1999, 45(2): 427-34.
[6] 漆松涛,刘承勇.脑转移瘤的X刀治疗与常规手术疗效比较[J].第一军医大学学报(J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao),2000,20(2):150-1.
[7] Aoyama H, Shirato H, Onimaru R, et al. Hypofractionated stereotactic radiotherapy alone without whole-brain irradiation for patients with solitary and oligo brain metastasis using noninvasive fixation of the skull[J]. Int J Radiat Oncol Biol Phys, 2003, 56(3): 793-800.
[8] DeAngelis L, Delattre J, Posner J. Radiation induced dementia in patients cured of brain metastases[J]. Neurology, 1989, 39(6): 789-96.
[9] Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases[J]. Int J Radiat Oncol Biol Phys, 2002, 53(3): 519-26.
[10] Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: Is whole brain radiotherapy necessary[J]. Int J Radiat Oncol Biol Phys, 1999, 43(3): 549-58.
[11] Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases[J]. J Clin Oncol, 1998, 16(11): 3563-9.
[12] Regine WF, Huhn JL, Patchell RA, et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications[J]. Int J Radiat Oncol Biol Phys, 2002, 52(2): 333-8.
[13] Christina A, Meyers D, Jennifer A, et al. Neurocognitive function and progression in patients with brain met-astases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase Ⅲ trial[J]. J Clin Oncol, 2004, 22(1): 157-65.
[14] Zabel A, Debus J. Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy[J]. Lung Cancer, 2004, 45(Suppl 2): 247-52.
[15] Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial Irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: Long-term follow-up and investigations of late neuropsychologic effects[J]. J Clin Oncol, 1999, 17(9):2700-9.
[16] Gerosa M, Nicolato A, Foroni R. Analysis of long-term outcomes and prognostic factors in patients with non-small cell lung cancer brain metastases treated by gamma knife radiosurgery[J]. J Neurosurg, 2005, 102 (Suppl):75-80.